Quantcast

Latest Sunitinib Stories

2008-10-27 12:00:30

Infinity Pharmaceuticals, a cancer drug discovery and development company, has initiated a Phase III registration trial of IPI-504, its lead inhibitor of heat shock protein 90, in patients with refractory gastrointestinal stromal tumors. The Ring trial is a randomized, double-blind, placebo-controlled study evaluating approximately 200 patients with refractory gastrointestinal stromal tumors (GIST) in over 20 countries and 50 sites worldwide. Patients whose tumors have grown despite...

2008-10-23 09:00:38

ZymoGenetics, a developer of novel protein therapeutics, has announced positive interim results from a Phase II clinical trial evaluating interleukin 21 in combination with Nexavar tablets in patients with metastatic renal cell cancer. Outpatient therapy with interleukin 21 (IL-21) and Nexavar as a second or third-line therapy for metastatic renal cell cancer was associated with anti-tumor activity, with manageable side effects. Of subjects treated and assessed by independent review, three...

2008-10-22 15:00:13

CAMBRIDGE, Mass., Oct. 22 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced new data from early non-clinical studies of Millennium/Takeda-discovered pipeline molecules highlighting novel therapeutic pathways in oncology. MLN4924 data build on the growing body of evidence supporting the importance of the Millennium-discovered Nedd8 Activating Enzyme (NAE) in tumor growth and survival. It is a first-in-class small molecule inhibitor of NAE. Both clinical and non-clinical...

2008-10-22 06:00:08

ZymoGenetics, Inc. (NASDAQ: ZGEN) presented interim results today from a Phase 2 clinical trial evaluating Interleukin 21 (IL-21) in combination with Nexavar(R) (sorafenib) tablets in patients with metastatic renal cell cancer. Outpatient therapy with IL-21 and Nexavar as a second or third-line therapy for metastatic renal cell cancer was associated with anti-tumor activity, with manageable side effects. Of subjects treated and assessed by independent review, 3 of 18 patients had a confirmed...

2008-10-16 09:00:42

Exelixis, Inc. (Nasdaq:EXEL) announced today that it will present 15 posters on the company's investigational compounds at the 20th Annual European Organization for Research and Treatment of Cancer-National Cancer Institute-American Academy of Cancer Research (EORTC-NCI-AACR) Symposium on "Molecular Targets and Cancer Therapeutics," which will be held October 21-October 24 in Geneva, Switzerland. The titles, schedules, and locations for the poster presentations are provided below. Note that...

2008-10-14 09:00:45

WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, of the many targeted cancer agents in Phase III clinical trials in the adjuvant setting, surveyed oncologists say that Genentech/Roche/Chugai's Avastin in early-stage colorectal cancer holds the most promise to achieve regulatory approval. Additionally, more than half of surveyed oncologists indicated that the minimum benefit...

2008-09-30 09:00:17

Pfizer Inc today provided the latest update to its development pipeline, showing significant progress in achieving the company's growth, productivity and performance goals. The pipeline now includes 114 programs, from Phase 1 through Registration. The number in late-stage (Phase 3) development has grown from 16 to 25 over the past six months. In total, 31 programs advanced to the next stage of development; 13 were discontinued; and one was withdrawn from registration. The majority...

2008-09-26 18:00:59

GRANDMOTHER Dorothy Isgrove, who was diagnosed with bowel cancer six years ago, has spoken of her daily battle to keep up her spirits and deal with her illness. Dorothy, who recently won her battle with health officials to be prescribed the expensive cancer drug Sutent, said she was now feeling much more positive although checks still have to be made on whether the drug is working. Dorothy and husband Brian re-mortgaged their home, raising pounds 40,000, after health officials refused...

2008-09-24 18:00:00

By Emma Brady Considering the current state of Britain's housing market, anyone hoping to make a sale must be desperate to move. Stephen Allen was so desperate that in a short space of time he moved from both Worcestershire and the Black Country because his local primary care trusts would not fund kidney cancer drug Sutent (sunitinib) - which cost more than pounds 3,000 a course. The trust stated it was too expensive to justify the extra months of life he might get. But when he...

2008-09-24 18:00:14

A SENIOR civil servant, diagnosed with terminal cancer and denied treatment with a new drug, has taken his campaign to the National Assembly calling for an end to the postcode lottery. Former Brecon town mayor Chris Lewis, who has been given two years to live, said he is now fighting for thousands of others who are terminally ill and would even refuse the drug treatment unless it was prescribed to all patients in his situation. The grandfather-of-four is calling on Welsh Health Minister...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related